Screener
BioCryst Pharmaceuticals BCRX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $218.25M+33.6% | $156.41M+7.5% | $406.56M+209% | $159.4M+36.1% | $163.35M+49.4% | ||
| $3.84M+37.2% | $5.38M+17.7% | $9.52M+56.3% | $2.19M-31.9% | $2.8M+64.7% | ||
| $214.41M+33.5% | $151.04M+7.1% | $397.03M+217% | $157.21M+38.1% | $160.56M+49.2% | ||
| 98.2%0.0pp | 96.6%-0.3pp | 97.7%+2.3pp | 98.6%+1.4pp | 98.3%-0.2pp | ||
| $51.97M+19.8% | $60.32M+61.8% | $40.87M-17.3% | $44.6M+8.6% | $43.39M+15.3% | ||
| $63.98M-26.8% | $94.55M+14.7% | $95.78M+19.0% | $83.01M+27.5% | $87.38M+42.7% | ||
| $119.79M-10.3% | $858.01M+590% | $146.17M+7.4% | $129.8M+18.7% | $133.57M+32.8% | ||
| $98.47M+231% | -$701.6M-3,405% | $260.39M+5,876% | $29.59M+285% | $29.79M+240% | ||
| 45.1%+26.9pp | -448.6%-463pp | 64%+67.5pp | 18.6%+12.0pp | 18.2%+10.2pp | ||
| $21.71M+0.6% | $19.78M-15.8% | $14.14M-42.2% | $19.66M-20.8% | $21.58M-12.7% | ||
| -$18.99M+18.5% | -$19.21M+6.2% | -$12.37M+42.4% | -$17.46M+17.4% | -$23.3M-9.6% | ||
| $79.47M+1,125% | -$720.81M-95,193% | $248.02M+1,054% | $12.13M+190% | $6.49M+152% | ||
| $1.08M-23.0% | $1M+38.3% | $2.17M+170% | -$769K-231% | $1.4M+715% | ||
| $78.4M+1,442% | -$721.81M-2,255,763% | $245.85M+1,018% | $12.9M+192% | $5.09M+140% | ||
| 35.9%+32.8pp | -461.5%-462pp | 60.5%+80.8pp | 8.1%+20.1pp | 3.1%+14.7pp | ||
| $0.30+1,400% | -$2.98— | $1.13+969% | $0.06+186% | $0.02+133% | ||
| $98.98M+229% | -$700.54M-3,350% | $260.78M+6,311% | $29.93M+274% | $30.12M+232% | ||
| 45.4%+26.9pp | -447.9%-463pp | 64.1%+67.3pp | 18.8%+11.9pp | 18.4%+10.1pp | ||
| $98.47M+231% | -$701.6M-3,405% | $260.39M+5,876% | $29.59M+285% | $29.79M+240% |
FAQ
- What is BioCryst Pharmaceuticals's revenue?
- BioCryst Pharmaceuticals (BCRX) generated $940.6M in revenue over the trailing twelve months, up 68.7% year over year.
- Is BioCryst Pharmaceuticals profitable?
- BioCryst Pharmaceuticals is not currently profitable: it reported a net loss of $384.7M over the trailing twelve months, a -40.9% net margin.
- What are BioCryst Pharmaceuticals's profit margins?
- Gross margin is 97.8% and operating margin is -33.3%, with a -40.9% net margin.
- What is BioCryst Pharmaceuticals's earnings per share?
- BioCryst Pharmaceuticals's diluted EPS over the trailing twelve months is $-1.49.
- Where does BioCryst Pharmaceuticals's income statement data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
